EVALUATING THE ANTI-INFLAMMATORY POTENTIAL OF GAMMA ORYZANOL FROM ORYZA SATIVA BY TARGETING THE NF-KB PATHWAY: A MOLECULAR DOCKING AND STRUCTURE-BASED PHARMACOPHORE MODELING APPROACH
DOI:
https://doi.org/10.22159/ijap.2026v18i2.57648Keywords:
Gamma oryzanol, Nuclear factor kappa beta, Polycystic ovary syndrome, Infertility, Pharmacophore modelingAbstract
Objective: The nuclear factor kappa-B (NF-κB) pathway is a key regulator of inflammation observed in polycystic ovary syndrome (PCOS), rendering it a promising target for treatment. Gamma oryzanol (γ-oryzanol) has been reported to display anti-inflammatory properties. However, the particular γ-oryzanol compounds and their specific molecular mechanism by which γ-oryzanol interacts and modulates NF-κB activity have yet to be explained. The study intended to explore the molecular interactions underlying the anti-inflammatory activity of γ-oryzanol against NF-κB through in silico molecular docking and structure-based pharmacophore modeling.
Methods: A receptor-based pharmacophore model was created from the ligand-binding site of the NF-κB through the Molecular Operating Environment 2019 software. The pharmacophore comprised four features: one hydrogen bond donor, one hydrogen bond acceptor, one aromatic, and one hydrophobic feature. The optimized model was used to screen an in-house phytochemical database to find the hit compounds with matching features, followed by molecular docking of hit compounds to evaluate their binding manners and interactions with NF-κB. The docking poses were analyzed for key interactions and ranked based on their docking scores.
Results: Four lead compounds that satisfied the pharmacophore query were 24-methylenecycloartenyl ferulate, cycloartenyl ferulate, campesteryl ferulate, and β-sitosteryl ferulate. The docking results showed that 24-methylenecycloartenyl ferulate had the most potent interaction with NF-kB (-6.9 Kcal/mol), followed by cycloartenyl ferulate (-6.7 Kcal/mol), campesteryl ferulate (-5.9 Kcal/mol), and β-sitosteryl ferulate (-5.1 Kcal/mol), indicating their potential to modulate NF-κB.
Conclusion: The present study provides molecular insights into the potential modulatory mechanism of γ-oryzanol against NF-κB. γ-oryzanol, along with structurally related phytochemicals, may serve as a promising scaffold for targeting NF–κB–mediated inflammation, implicated in PCOS. These computational predictions offer a foundation for experimental validation in related inflammatory disease models.
References
1. Siddiqua A, Malik A, Iqbal U, Sial NT, Mehmood MH, Rehman MF. Antioxidative and anti-inflammatory effects of carvacrol against polycystic ovary syndrome-associated complications using high fat diet and letrozole challenged rat model: a multidisciplinary study cascading in vivo, in vitro, in silico and network pharmacology approaches. Inflammopharmacology. 2025 Jun 20;33(8):4703-24. doi: 10.1007/s10787-025-01809-8, PMID 40540113.
2. Hu M, Zhang Y, Li X, Cui P, Sferruzzi Perri AN, Brannstrom M. TLR4-associated IRF-7 and NFκB signaling act as a molecular link between androgen and metformin activities and cytokine synthesis in the PCOS endometrium. J Clin Endocrinol Metab. 2021 Apr 1;106(4):1022-40. doi: 10.1210/clinem/dgaa951, PMID 33382900.
3. Pachiappan S, Arul Balasubramanian MG, Ramalingam K. Pharmacoinformatics-based in silico molecular dynamics simulation for screening phytochemicals as AMPK and INSR modulators for polycystic ovarian syndrome from medicinal plants. International Journal of Pharmaceutical Sciences and Research. 2023;15:1087-92.
4. Rostamtabar M, Esmaeilzadeh S, Tourani M, Rahmani A, Baee M, Shirafkan F. Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome. J Cell Physiol. 2021;236(2):824-38. doi: 10.1002/jcp.29912, PMID 32617971.
5. Tan W, Zhang J, Dai F, Yang D, Gu R, Tang L. Insights on the NF-κB system in polycystic ovary syndrome: attractive therapeutic targets. Mol Cell Biochem. 2024;479(3):467-86. doi: 10.1007/s11010-023-04736-w, PMID 37097332.
6. Lakshmi JN, Babu AN, Kiran SS, Nori LP, Hassan N, Ashames A. Herbs as a source for the treatment of polycystic ovarian syndrome: a systematic review. BioTech (Basel). 2023;12(1):4. doi: 10.3390/biotech12010004, PMID 36648830.
7. Pavithra L, Ilango K. Identification of phytoconstituents for combating polycystic ovarian syndrome through in silico techniques. Indian J Biochem Biophys. 2023 Jun 27;60(2):99-107. doi: 10.56042/ijbb.v60i2.70682.
8. Chakraborty S, Khurana N, Kaur J, Mehta M, Sharma N. Gamma oryzanol: a natural compound with potential for treating polycystic ovary syndrome. Pharmacological Research Modern Chinese Medicine. 2024;13:100506. doi: 10.1016/j.prmcm.2024.100506.
9. Filho AC, Guedes MI, Duarte LS, Lima Neto AB, Cameron LC, Bassini A. Gamma-oryzanol has an equivalent efficacy as a lipid-lowering agent compared to fibrate and statin in two dyslipidemia mice models. Int J Pharm Pharm Sci. 2014;6(11):61-4.
10. Alizadeh M, Moshtagh S, Abdolalizadeh Amir S, Jeddi M, Tahmasebzadeh S, Radman G. Anti-oxidant and anti-apoptotic effects of gamma-oryzanol on male reproductive function in chronic restraint stress in rats. Avicenna J Phytomed. 2025;15(1):890-906. doi: 10.22038/AJP.2024.24819, PMID 40271500.
11. Radda MI, Omar N, Yusof SF, Ahmad R, Rohana AJ, Ishak WR. Effectiveness of gamma-oryzanol in glycaemic control and managing oxidative stress, inflammation and dyslipidaemia in diabetes: a systematic review of preclinical studies. Peer J. 2025 Sep 23;13:e20062. doi: 10.7717/peerj.20062, PMID 41018904.
12. Panyathep A, Punturee K, Chewonarin T. Gamma-oryzanol-rich fraction from purple rice extract attenuates lipopolysaccharide-stimulated inflammatory responses, migration and VEGFA production in SW480 cells via modulation of TLR4 and NF-κB pathways. Nutr Cancer. 2022 Jul 3;74(6):2254-64. doi: 10.1080/01635581.2021.2002921, PMID 34766845.
13. Chauhan A, Kamal R, Kumar M, Singh TG, Vishwas S, Awasthi A. Exploring the mechanisms and therapeutic role of γ-oryzanol in neuropathic pain: a systematic review. Inflammopharmacology. 2025 Dec 24:1-29. doi: 10.1007/s10787-025-02100-6, PMID 41442076.
14. Pratap Reddy Gajulapalli V, Lee J, Sohn I. Ligand-based pharmacophore modelling in search of novel anaplastic lymphoma kinase inhibitors. Results Chem. 2023;5:100752. doi: 10.1016/j.rechem.2022.100752.
15. Lin CT, Lin LW, Chang LC, Wu LY, Tsai FS. Combining network pharmacology, molecular docking and integrative studies to explore the mechanism of helminthostachys zeylanica in alleviating ulcerative colitis. Food Sci Nutr. 2025 Nov;13(11):e71139. doi: 10.1002/fsn3.71139, PMID 41164267.
16. Martis EA, Teletchea S. Ten quick tips to perform meaningful and reproducible molecular docking calculations. PLOS Comput Biol. 2025 May 9;21(5):e1013030. doi: 10.1371/journal.pcbi.1013030, PMID 40344147.
17. Muhammed MT, Aki-Yalcin E. Pharmacophore modeling in drug discovery: methodology and current status. Journal of the Turkish Chemical Society Section A. 2021;8(3):749-62. doi: 10.18596/jotcsa.927426.
18. Dayrit FM, Guidote AM, Gloriani NG, De Paz-Silava SL, Villasenor IM, Macahig RA. Philippine medicinal plants with potential immunomodulatory and anti-SARS-CoV-2 activities. Philipp J Sci. 2021;150(5):999-1015. doi: 10.56899/150.05.12.
19. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766-88. doi: 10.1016/j.apsb.2020.02.008, PMID 32292689.
20. Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. J Biomol Struct Dyn. 2021;39(9):3194-203. doi: 10.1080/07391102.2020.1761881, PMID 32340551.
21. Kori MA, Panera BH, Buwa VA. Molecular docking of phytochemicals as inhibitors of EGFR in non-small cell lung cancer. Innov J Med Sci. 2022;10(4):28-30. doi: 10.22159/ijms.2022v10i4.45085.
22. Gentile D, Patamia V, Scala A, Sciortino MT, Piperno A, Rescifina A. Putative inhibitors of SARS-COV-2 main protease from a library of marine natural products: a virtual screening and molecular modeling study. Mar Drugs. 2020;18(4):225. doi: 10.3390/md18040225, PMID 32340389.
23. Marchev AS, Yordanova ZP, Georgiev MIG. Green (cell) factories for advanced production of plant secondary metabolites. Crit Rev Biotechnol. 2020;40(4):443-58. doi: 10.1080/07388551.2020.1731414, PMID 32178548.
24. Han T, Miao G. Strategies, achievements and potential challenges of plant and microbial chassis in the biosynthesis of plant secondary metabolites. Molecules. 2024 May 2;29(9):2106. doi: 10.3390/molecules29092106, PMID 38731602.
25. Baixinho JP, Cardeira M, Bento Silva A, Partidario AM, Serra AT, Bronze MD. Optimization of supercritical fluid extraction for the recovery of γ-oryzanol-rich extracts with improved bioactivity from rice bran. Antioxidants (Basel). 2025 Feb 11;14(2):206. doi: 10.3390/antiox14020206, PMID 40002392.
26. Fioranelli M, Roccia MG, Flavin D, Cota L. Regulation of inflammatory reaction in health and disease. Int J Mol Sci. 2021 May 17;22(10):5277. doi: 10.3390/ijms22105277, PMID 34067872.
27. Kannan G, Paul BM, Thangaraj P. Stimulation regulation and inflammaging interventions of natural compounds on nuclear factor kappa B (NF-kB) pathway: a comprehensive review. Inflammopharmacology. 2025 Jan;33(1):145-62. doi: 10.1007/s10787-024-01635-4, PMID 39776026.
28. Mao H, Zhao X, Sun SC. NF-κB in inflammation and cancer. Cell Mol Immunol. 2025;22(8):811-39. doi: 10.1038/s41423-025-01310-w, PMID 40562870.
29. Nikooyeh B, Zargaraan A, Ebrahimof S, Kalayi A, Zahedirad M, Yazdani H. Added γ-oryzanol boosted anti-inflammatory effects of canola oil in adult subjects with type 2 diabetes: a randomized controlled clinical trial. Eur J Nutr. 2024 Mar;63(2):425-33. doi: 10.1007/s00394-023-03275-w, PMID 37971692.
30. Sari Aslani K, Davoodian N, Zeini S, Mousavi SA, Eftekhar E. γ-oryzanol ameliorates the oxidative stress and inflammatory response in a mice model of LPS-induced liver injury. Dis Diagn. 2024 Sep 5;13(3):107-13. doi: 10.34172/ddj.1585.
31. Ali MA, Chew SC, Lin Nyam K, Aryusuk K. Green extraction technologies antioxidant mechanism and therapeutic potentials of gamma-oryzanol. Food Rev Int. 2025 Jun 20:1-37. doi: 10.1080/87559129.2025.2521362.
32. Lisnawati L, Poeranto S, Endharti AT, Santoso MI. Antioxidant and anti-inflammatory activity of γ-oryzanol compared to rice bran oil to repair ovarian histological structure from one push transfluthrin exposure effect. Open Access Maced J Med Sci. 2022 Jan 1;10(B):1-12. doi: 10.3889/oamjms.2022.7543.
33. Tsai KC, Teng LW, Shao YM, Chen YC, Lee YC, Li M. The first pharmacophore model for potent NF-κB inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5665-9. doi: 10.1016/j.bmcl.2009.08.021, PMID 19726185.
34. Al Mousa AA, Abouelela ME, Mansour A, Nasr M, Ali YH, Al Ghamidi NS. Wound healing metabolite profiling and in silico studies of Aspergillus terreus. Curr Issues Mol Biol. 2024 Oct 19;46(10):11681-99. doi: 10.3390/cimb46100694, PMID 39451574.
35. Wang P, Zhang R, Liu M, Gao J, Zhang Y, Liu X. Exploring the effect and mechanism of baicalin on sepsis-induced acute lung injury based on network pharmacology and experimental verification. Sci Rep. 2025 Nov 25;15(1):41959. doi: 10.1038/s41598-025-25943-z, PMID 41290918.
36. Chen FE, Huang DB, Chen YQ, Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature. 1998 Jan 22;391(6665):410-3. doi: 10.1038/34956, PMID 9450761.
37. Natarajan K, Singh S, Burke Jr TR, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA. 1996 Aug 20;93(17):9090-5. doi: 10.1073/pnas.93.17.9090, PMID 8799159.
38. Xia YF, Ye BQ, Li YD, Wang JG, He XJ, Lin X. Andrographolide attenuates inflammation by inhibition of NF-κB activation through covalent modification of reduced cysteine 62 of p50. J Immunol. 2004 Sep 15;173(6):4207-17. doi: 10.4049/jimmunol.173.6.4207, PMID 15356172.
39. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010;1799(10-12):775-87. doi: 10.1016/j.bbagrm.2010.05.004, PMID 20493977.
40. Islam A, Jena D, Mondal NS, Teli A, Mondal S, Gautam MK. In silico approaches for drug designing technology: bridging discovery and development. Curr Drug Discov Technol. 2025 Sep;22(5):706-16. doi: 10.2174/0115701638326869250207060616, PMID 39966365.
41. Vazquez J, Lopez M, Gibert E, Herrero E, Luque FJ. Merging ligand-based and structure-based methods in drug discovery: an overview of combined virtual screening approaches. Molecules. 2020 Oct 15;25(20):4723. doi: 10.3390/molecules25204723, PMID 33076254.
42. Ancuceanu R, Lascu BE, Draganescu D, Dinu M. In silico ADME methods used in the evaluation of natural products. Pharmaceutics. 2025 Jul 31;17(8):1002. doi: 10.3390/pharmaceutics17081002, PMID 40871023.
43. Ito J, Sawada K, Ogura Y, Xinyi F, Rahmania H, Mohri T. Definitive evidence of the presence of 24-methylenecycloartanyl ferulate and 24-methylenecycloartanyl caffeate in barley. Sci Rep. 2019 Aug 29;9(1):12572. doi: 10.1038/s41598-019-48985-6, PMID 31467350.
Published
How to Cite
Issue
Section
Copyright (c) 2026 AASIA KANWAL, MUHAMMAD HAMDI MAHMOOD, SAIFUL BAHRI TALIP, NORHIDA RAMLI
This work is licensed under a Creative Commons Attribution 4.0 International License.